Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.4% After Insider Selling

Gyre Therapeutics, Inc. (NASDAQ:GYRE) fell 4.4% during trading on Tuesday after an insider sold shares in the company. The company traded as low as $12.10 and last traded at $12.10. 38,531 shares changed hands during trading, a decline of 49% from the average session volume of 75,509 shares. The stock had previously closed at $12.66.

Specifically, President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the sale, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Gyre Therapeutics Stock Down 4.3 %

The company’s 50 day moving average price is $12.71 and its 200-day moving average price is $12.66.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. FMR LLC acquired a new position in shares of Gyre Therapeutics in the 3rd quarter worth $47,000. Barclays PLC boosted its position in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares during the period. Rhumbline Advisers purchased a new position in Gyre Therapeutics in the 2nd quarter worth about $123,000. Renaissance Technologies LLC purchased a new stake in Gyre Therapeutics during the second quarter valued at about $166,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Gyre Therapeutics in the second quarter worth about $218,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.